Hehuang Pharmaceutical (00013) rose 5% in the afternoonbbetpoker.39%bbetpoker, currently reported at HK$28.35, with a turnover of HK$103 million.
Ping An Securities pointed out that sales of the company's core products have maintained rapid growth. Fruquintinib was launched in the United States in November 2023. It is the first innovative targeted therapy approved in the United States for the treatment of metastatic colorectal cancer in more than a decade., only two months after its launch, sales in the U.S. market have reached US$15.1 million, which is rapidly increasing.
